Press release
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
Supports broader adoption of Natera’s RenasightTM test AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
About this update from Natera, Inc.
[{"type":"text","content":"\nSupports broader adoption of Natera’s RenasightTM test\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, which was recently published by the Kidney Disease Improving Global Outcomes (KDIGO) organization, a leading medical society in nephrology. The updated guideline includes consensus statements supporting the use of genetic testing to establish the cause of chronic kidney disease (CKD) for a majority of patients with this condition.\n\n\nThe KDIGO guideline, specifically in Practice Points 1.1.4.1 and 1.1.4.2, states that genetic tests should be used, among other factors, to establish cause for CKD, and that genetic testing can impact the clinical management of people with CKD. The guideline also emphasizes that genetic causes may be present even without a family history; and it references six clinical scenarios, covering the majority of CKD patients, where genetic testing is particularly informative, including:\n\n\n\nConditions with high prevalence of monogenic subtypes within the clinical category;\n\n\n\nEarly age of onset of CKD;\n\n\n\nSyndromic/multisystem features;\n\n\n\nConsanguinity;\n\n\n\nPossibility of identifying a condition amenable to targeted treatment; and\n\n\n\nCKD/ESRD of unknown etiology when kidney biopsy would not be informative due to advanced disease.\n\n\n\nThe guideline also lists specific gene categories, aligned with Natera’s Renasight gene panel, that are actionable for CKD patients.\n\n\n“KDIGO makes it clear that most CKD patients and healthcare providers would prefer to identify the underlying cause of disease, which should include a genetic diagnosis when such tests are available,” said Maggie Westemeyer, MS, CGC, and director of clinical genetic services at Natera. “This is where Natera plays a key role, providing access both to our Renasight test and to our genetic educational resources to enable guideline-recommended care.”\n\n\nThe guideline was released following the publication of the landmark RenaCARE study – a multisite, prospective study demonstrating the diagnostic and clinical utility of Renasight in 1,623 patients with CKD. More than 55% of all U.S. nephrologists have ordered the Renasight test.\n\n\nAbo...